{"id":922986,"date":"2025-12-30T10:08:42","date_gmt":"2025-12-30T15:08:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/"},"modified":"2025-12-30T10:08:42","modified_gmt":"2025-12-30T15:08:42","slug":"exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/","title":{"rendered":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims"},"content":{"rendered":"
\n

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott\u2019s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low.<\/p>\n

For a free consultation, please visit https:\/\/julieholleman.com\/exact-sciences-corp\/<\/a>, or contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com<\/a>.<\/p>\n

The deal was announced in November and is expected to close in the second quarter of 2026.<\/p>\n

On December 29, 2025, Exact Sciences filed a preliminary proxy statement with the SEC in connection with the upcoming shareholder vote on the merger. The proxy statement reveals a process where no other bidders were considered. Moreover, one of the company\u2019s financial advisors indicated that Exact Sciences could be worth as much as $136.25 per share.<\/p>\n

Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating potential claims based on the apparent unfairness of the deal, as well as potential conflicts of interest.<\/p>\n

If you would like more information, please visit https:\/\/julieholleman.com\/exact-sciences-corp\/<\/a>, or contact partner Scott Holleman at (929) 415-1020 or scott@julieholleman.com<\/a>.<\/p>\n

FIRM INFORMATION<\/p>\n

Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm\u2019s attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com<\/a>. This notice may constitute attorney advertising.<\/p>\n

Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott\u2019s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low. For a free consultation, please visit https:\/\/julieholleman.com\/exact-sciences-corp\/, or contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. The deal was announced in November and is expected to close in the second quarter of 2026. On December 29, 2025, Exact Sciences filed a preliminary proxy statement with the SEC in connection with the upcoming shareholder vote on the merger. The proxy statement reveals a process where no other bidders … <\/p>\n

Continue reading “Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-922986","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nExact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott\u2019s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low. For a free consultation, please visit https:\/\/julieholleman.com\/exact-sciences-corp\/, or contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. The deal was announced in November and is expected to close in the second quarter of 2026. On December 29, 2025, Exact Sciences filed a preliminary proxy statement with the SEC in connection with the upcoming shareholder vote on the merger. The proxy statement reveals a process where no other bidders … Continue reading "Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-30T15:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims\",\"datePublished\":\"2025-12-30T15:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/\",\"name\":\"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=\",\"datePublished\":\"2025-12-30T15:08:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/","og_locale":"en_US","og_type":"article","og_title":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk","og_description":"NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) — Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott\u2019s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low. For a free consultation, please visit https:\/\/julieholleman.com\/exact-sciences-corp\/, or contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. The deal was announced in November and is expected to close in the second quarter of 2026. On December 29, 2025, Exact Sciences filed a preliminary proxy statement with the SEC in connection with the upcoming shareholder vote on the merger. The proxy statement reveals a process where no other bidders … Continue reading \"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-30T15:08:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims","datePublished":"2025-12-30T15:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/","name":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=","datePublished":"2025-12-30T15:08:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxODIwNSM3MzM5NzQxIzIyOTI2MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exact-sciences-shareholders-unhappy-with-105-per-share-sale-to-abbott-should-contact-julie-holleman-llp-regarding-potential-claims\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=922986"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/922986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=922986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=922986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=922986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}